Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 38, 2015, Pages E5290-E5299

  Bartkowiak, Todd ^a,b   Singh, Shailbala ^a   Yang, Guojun ^a   Galvan, Gloria ^a,b   Haria, Dhwani ^a   Ai, Midan ^a   Allison, James P ^a,b   Sastry, K Jagannadha ^a,b   Curran, Michael A ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

4 1BB; Cancer vaccine; Checkpoint blockade; HPV; Immunotherapy

Indexed keywords

4 1BB AGONIST ANTIBODY; ALPHA GALACTOSYLCERAMIDE; ANTIBODY; INDUCIBLE T CELL COSTIMULATOR; PEPTIDE VACCINE; PROTEIN E6; PROTEIN E7; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; CD137 ANTIGEN; CYTOKINE; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 1; ONCOPROTEIN; PEPTIDE; SUBUNIT VACCINE; WART VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; MONOTHERAPY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER; WART VIRUS; AGONISTS; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CELL SEPARATION; CHEMISTRY; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PAPILLOMAVIRIDAE; PATHOLOGY; PROCEDURES; SPLEEN; VAGINA;

ANIMALS; ANTIBODIES; ANTIGENS, CD137; CELL SEPARATION; CYTOKINES; FEMALE; FLOW CYTOMETRY; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS VACCINES; PEPTIDES; SPLEEN; VACCINES, SUBUNIT; VAGINA;

EID: 84942877676     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1514418112     Document Type: Article

References (33)

1. Parkin DM, Pisani P, Ferlay J. (1999) Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80(6):827-841.
2. Moody CA, Laimins L.A. (2010) Human papillomavirus oncoproteins: Pathways to transformation. Nat Rev Cancer 10(8):550-560.
3. Chaturvedi AK (2010) Beyond cervical cancer: Burden of other HPV-related cancers among men and women. J Adolesc Health 46(4, Suppl):S20-S26.
4. Brinkman JA, et al (2007) Therapeutic vaccination for HPV induced cervical cancers. Dis Markers 23(4):337-352.
5. Gajewski TF, Louahed J, Brichard V.G. (2010) Gene signature in melanoma associated with clinical activity: A potential clue to unlock cancer immunotherapy. Cancer J 16(4): 399-403.
6. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252-264.
7. Curran MA, Montalvo W, Yagita H, Allison J.P. (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 107(9):4275-4280.
8. Wolchok JD, et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369(2):122-133.
9. Moran AE, Kovacsovics-Bankowski M, Weinberg A.D. (2013) The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol 25(2):230-237.
10. Curran MA, et al (2013) Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J Exp Med 210(4):743-755.
11. Sarkar AK, Tortolero-Luna G, Follen M, Sastry K.J. (2005) Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study. Gynecol Oncol 99(3, Suppl 1):S251-S261.
12. Manuri PR, et al (2007) Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine 25(17):3302-3310.
13. Lin KY, et al (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56(1):21-26.
14. Kim D, Hung CF, Wu TC, Park Y.M. (2010) DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells. Vaccine 28(45):7297-7305.
15. Zwaveling S, et al (2002) Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 169(1):350-358.
16. Rampias T, Sasaki C, Weinberger P, Psyrri A. (2009) E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst 101(6):412-423.
17. Sun Y, et al (2015) Intravaginal HPV DNA vaccination with electroporation induces local CD8+ T-cell immune responses and antitumor effects against cervicovaginal tumors. Gene Ther 22(7):528-535.
18. Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison J.P. (2011) Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 6(4):e19499.
19. Quezada SA, Peggs KS, Curran MA, Allison J.P. (2006) CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 116(7):1935-1945.
20. Selby MJ, et al (2013) Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 1(1):32-42.
21. Simpson TR, et al (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210(9):1695-1710.
22. Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison J.P. (2014) Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med 211(4):715-725.
23. Fu T, He Q, Sharma P. (2011) The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res 71(16):5445-5454.
24. Song C, et al (2014) Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy. OncoImmunology 3(1):e27680.
25. Decrausaz L, et al (2011) A novel mucosal orthotopic murine model of human papillomavirus-associated genital cancers. Int J Cancer 128(9):2105-2113.
26. Wang L, et al (2009) IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206(7):1457-1464.
27. Medema JP, et al (2001) Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: Differential modulation by T helper type 1 and type 2 cells. J Exp Med 194(5):657-667.
28. Srivastava AK, et al (2014) SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines. Cancer Res 74(22): 6441-6451.
29. Gubin MM, et al (2014) Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515(7528):577-581.
30. Badoual C, et al (2013) PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 73(1): 128-138.
31. Bergot AS, Kassianos A, Frazer IH, Mittal D. (2011) New approaches to immunotherapy for HPV associated cancers. Cancers (Basel) 3(3):3461-3495.
32. Courtney AN, et al (2009) Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens. Vaccine 27(25-26): 3335-3341.
33. Courtney AN, et al (2011) Intranasal but not intravenous delivery of the adjuvant α-galactosylceramide permits repeated stimulation of natural killer T cells in the lung. Eur J Immunol 41(11):3312-3322.